The following are some of the biotech stocks drawing investor attention in premarket trading today.
Shares of Upstream Bio Inc. (UPB), a clinical-stage company developing treatments for inflammatory diseases, are up over 14% at $7.48 in premarket trading Thursday. The company made its debut on the Nasdaq Global Market on October 11, 2024, under the ticker symbol "UPB", priced at $17 per share. The 180-day lockup period expired yesterday. Its lead drug candidate is Verekitug, which is under a phase II trial in patients with chronic rhinosinusitis with nasal polyps, with top-line data expected in the second half of 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com